Sildenafil
- Generic Name
- Sildenafil
- Brand Names
- Liqrev, Revatio, Viagra, Vizarsin, Sildenafil Actavis, Sildenafil ratiopharm, Granpidam, Sildenafil Teva, Mysildecard
- Drug Type
- Small Molecule
- Chemical Formula
- C22H30N6O4S
- CAS Number
- 139755-83-2
- Unique Ingredient Identifier
- 3M7OB98Y7H
- Background
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) . The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently faci...
- Indication
Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:
(1) the treatment of erectile dysfunction ; and
(2) treatment of pulmonary hypertension, where:
...
- Associated Conditions
- Erectile Dysfunction, NYHA Functional Class II-III Pulmonary arterial hypertension, Premature Ejaculation, Pulmonary Arterial Hypertension (PAH)
- Associated Therapies
- -
Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction
- Conditions
- Interventions
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 21
- Registration Number
- NCT02442492
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
🇨🇦CHU Sainte-Justine, Montréal, Quebec, Canada
🇨🇦CHU de Quebec - Universite Laval, Quebec City, Quebec, Canada
Effect of Sildenafil for Sustained PAH After MV Surgery (SUPERIOR Trial)
- Conditions
- Interventions
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT02435303
Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
- Conditions
- Interventions
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 4
- Registration Number
- NCT02414204
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 400
- Registration Number
- NCT02387450
- Locations
- 🇫🇷
Centre hospitalier universitaire, Angers, France
PDEI Following Mitral Valve Surgery in Patients With Pulmonary Hypertension
- Conditions
- Interventions
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2018-06-26
- Target Recruit Count
- 60
- Registration Number
- NCT02378649
- Locations
- 🇮🇱
Cardiac Surgical Department, Leviev Heart Center, Ramat Gan, Tel Hashomer, Israel
A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women
- First Posted Date
- 2015-02-18
- Last Posted Date
- 2015-06-22
- Lead Sponsor
- Strategic Science & Technologies, LLC
- Target Recruit Count
- 21
- Registration Number
- NCT02364882
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
A Randomized Controlled Trial Evaluating Sildenafil Citrate in Relieving Ureteral Stent Related Symptoms
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 94
- Registration Number
- NCT02345980
- Locations
- 🇪🇬
Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
Management of Acute Preterm Labor: Nifedipen Alone or Combined With Cildenafil Citrate
- Conditions
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2016-06-22
- Lead Sponsor
- Al Hayat National Hospital
- Target Recruit Count
- 227
- Registration Number
- NCT02337881
- Locations
- 🇪🇬
Menoufia University, Shebin Elkom, Egypt
🇸🇦Alhayah national hospital, Abha, Saudi Arabia
Sildenafil in Heart Failure With Reactive Pulmonary Hypertension
- Conditions
- Interventions
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Maya Guglin
- Target Recruit Count
- 33
- Registration Number
- NCT02304705
- Locations
- 🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States
A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH
- Conditions
- Interventions
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2024-02-20
- Target Recruit Count
- 100
- Registration Number
- NCT02284737
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.